Основная статистика
| LEI | 549300BSQ0R4UZ5KX287 |
| CIK | 1100682 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Charles River Laboratories International, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 6, 2025 |
Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES SECOND-QUARTER 2025 RESULTS – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $3.12 – – Updates 2025 Guidance – WILMINGTON, MA, August 6, 2025 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2 |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpora |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| August 6, 2025 |
Exhibit 10.1 AMENDMENT NO.1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO.1 (this “Amendment”) to the Amended and Restated Employment Agreement by and between James C. Foster (the “Executive”) and Charles River Laboratories International, Inc., a Delaware corporation (the “Company” and, hereinafter collectively referred to as “parties”), dated as of May 18, 2021 (the “Employment Agreement”), is entere |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 20, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporati |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 251 Ballardvale Street Wilm |
|
| May 7, 2025 |
Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2025 RESULTS – First-Quarter Revenue of $984.2 Million – – First-Quarter GAAP Earnings per Share of $0.50 and Non-GAAP Earnings per Share of $2.34 – – Increases 2025 Guidance – – Repurchased $350 Million of Common Stock in First Quarter of 2025 – WILMINGTON, MA, May 7, 2025 – Charles River Laboratories International, Inc. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio |
|
| May 7, 2025 |
Exhibit 10.1 COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “Agreement”), dated as of May 6, 2025 (the “Effective Date”), is made by and among Elliott Investment Management L.P., a Delaware limited partnership, Elliott Associates, L.P., a Delaware limited partnership, and Elliott International, L.P., a Cayman Islands limited partnership (each, an “Elliott Party” and, collectively, the “Ell |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 29, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 7, 2025 |
Exhibit 99.1 NEWS RELEASE Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company’s Business – – Enters into Cooperation Agreement with Elliott Investment Manageme |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 20, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| February 19, 2025 |
Charles River Executive Separation Plan dated December 05, 2024 Exhibit 10.7 CHARLES RIVER EXECUTIVE SEPARATION PLAN (Last Revised on December 05, 2024) 1.1Background 1.2Purpose: The purpose of the Charles River Executive Separation Plan is to establish an equitable measure of compensation for employees of Charles River Laboratories International, Inc. and/or its subsidiaries (“the Company”) designated with a title of Vice President or higher (“Executives”) in |
|
| February 19, 2025 |
Charles River Laboratories amended and restated Deferred Compensation Plan, as amended Exhibit 10.13 AMENDED AND RESTATED DEFERRED COMPENSATION PLAN DOCUMENT February 8, 2006 (Amended December 2, 2008, July 20, 2011 April 22, 2021 and January 30, 2025) ARTICLE 1. INTRODUCTION Charles River Laboratories hereby establishes the Charles River Laboratories Deferred Compensation Plan effective as of January 1, 2006. The Company has established the Plan to attract, retain and motivate cert |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES IN |
|
| February 19, 2025 |
Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS AND PROVIDES 2025 GUIDANCE – Fourth-Quarter Revenue of $1.00 Billion and Full-Year Revenue of $4.05 Billion – – Fourth-Quarter GAAP Loss per Share of $(4.22) and Non-GAAP Earnings per Share of $2.66 – – Full-Year GAAP Earnings per Share of $0.20 and Non-GAAP Earnings per Share of $10.32 – – Pro |
|
| February 19, 2025 |
Subsidiaries of Charles River Laboratories International, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Nederland B.V. Netherlands 5 Charles River Laboratories Holding SAS France 6 Charles River Laboratories France C.R.L.F. SAS France 7 BioFocus DPI (Holdings) L |
|
| February 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 19, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 14, 2025 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| December 13, 2024 |
Exhibit 10.1 TENTH AMENDED AND RESTATED CREDIT AGREEMENT dated as of December 13, 2024 among CHARLES RIVER LABORATORIES INTERNATIONAL, INC., The Subsidiary Borrowers Party Hereto, The Lenders Party Hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent BANK OF AMERICA, N.A., CITIBANK, N.A., CITIZENS BANK, N.A., Td SECURITIES (usA) LLC, U.S. BANK NATIONAL ASSOCIATION and WELLS FARGO BANK, N.A. |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of |
|
| November 8, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Charles River Laboratories International, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 159864107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec |
|
| November 8, 2024 |
EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Charles River Laboratories International, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with th |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 28, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R |
|
| November 6, 2024 |
Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES THIRD-QUARTER 2024 RESULTS – Third-Quarter Revenue of $1.01 Billion – – Third-Quarter GAAP Earnings per Share of $1.33 and Non-GAAP Earnings per Share of $2.59 – – Updates 2024 Guidance – WILMINGTON, MA, November 6, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 202 |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpora |
|
| August 7, 2024 |
Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES SECOND-QUARTER 2024 RESULTS – Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 – – Board Approves New Stock Repurchase Authorization of $1.0 Billion – – Revises 2024 Guidance – WILMINGTON, MA, August 7, 2024 – Charles River Laboratories International, I |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 251 Ballardvale Street Wilm |
|
| May 10, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio |
|
| May 9, 2024 |
Exhibit 4.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee Subordinated Indenture Dated as of , 20 table of contents Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 6 Section 1.04. Rules |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 9, 2024 |
Exhibit 25.1 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) [] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. |
|
| May 9, 2024 |
Exhibit 4.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee Senior Indenture Dated as of , 20 table of contents Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Con |
|
| May 9, 2024 |
Press release dated May 9, 2024 Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2024 RESULTS – First-Quarter Revenue of $1.01 Billion – – First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 – – Updates 2024 Guidance – WILMINGTON, MA, May 9, 2024 – Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. Fo |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Charles River Laboratories International, Inc. |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
Sixth Amended and Restated By-laws. Exhibit 3.2 SIXTH AMENDED AND RESTATED BY-LAWS OF CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SIXTH AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS ARTICLE I - Stockholders 3 1.1 Place of Meetings 3 1.2 Annual Meeting 3 1.3 Special Meetings 3 1.4 Notice of Meeting 3 1.5 Voting List 4 1.6 Quorum 4 1.7 Adjournments 4 1.8 Voting and Proxies 4 1.9 Proxy Representation 4 1.10 Action at Meeting; Major |
|
| May 9, 2024 |
Exhibit 25.2 securities and exchange commission Washington, D.C. 20549 FORM T-1 Statement of Eligibility Under The Trust Indenture Act of 1939 of a Corporation Designated to Act as Trustee Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) [] U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| February 14, 2024 |
Exhibit 10.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED 2018 INCENTIVE PLAN Originally adopted by the Board of Directors On March 20, 2018 Approved at Annual Meeting of Shareholders On May 8, 2018 Amended by the Board of Directors On March 14, 2020 Amendment and Restatement Approved at Annual Meeting of Shareholders On May 6, 2020 Amended by the Administrator (the Compensa |
|
| February 14, 2024 |
Subsidiaries of Charles River Laboratories International, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Nederland B.V. Netherlands 5 Charles River Laboratories Holding SAS France 6 Charles River Laboratories France C.R.L.F. SAS France 7 BioFocus DPI (Holdings) L |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES IN |
|
| February 14, 2024 |
Financial Statement Compensation Recoupment Policy EXHIBIT 97 GLOBAL CORPORATE POLICY Doc #: GLBL-POL-00093 Rev #: 1 Effective Date: 2023/10/23 Policy Sponsor: Corporate Legal Title: Financial Statement Compensation Recoupment Policy PURPOSE This Policy provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements under U. |
|
| February 14, 2024 |
EXHIBIT 19 GLOBAL CORPORATE POLICY Doc #: GLBL-POL-00060 Rev #: 3 Effective Date: 19/Jan/2024 Policy Sponsor: Corporate Legal Title: Insider Trading Policy PURPOSE It is the policy of Charles River Laboratories International, Inc. |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 14, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe |
|
| February 14, 2024 |
Exhibit 10.6 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Unless defined in this Restricted Stock Unit Award (this “Award Document”), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the “Plan”). Pursuant to Section 4(c) of the Plan, you have been |
|
| February 14, 2024 |
Exhibit 99.1 Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 – – Provides 2024 |
|
| February 13, 2024 |
SC 13G/A 1 tv0582-charlesriverlaborator.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Charles River Laboratories International Inc Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 9, 2024 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpor |
|
| November 21, 2023 |
251 Ballardvale Street, Wilmington, Massachusetts 01887 VIA EDGAR November 21, 2023 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Technology Attn: Kristin Lochhead, Senior Staff Accountant Brian Cascio, Accounting Branch Chief Re: Charles River Laboratories International, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Form 8-K dated November 8, 2023 File No. 001-15943 Members of the Staff: Charles River L |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R |
|
| November 8, 2023 |
Charles River Laboratories Announces Third-Quarter 2023 Results Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2023 Results – Third-Quarter Revenue of $1.03 Billion – – Third-Quarter GAAP Earnings per Share of $1.69 and Non-GAAP Earnings per Share of $2.72 – – Updates 2023 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-November 8, 2023-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 9, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED July 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER L |
|
| August 9, 2023 |
Charles River Laboratories Announces Second-Quarter 2023 Results Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2023 Results – Second-Quarter Revenue of $1.06 Billion – – Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 – – Updates 2023 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-August 9, 2023-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter o |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or other jurisdiction (Commission (IRS Employer of incorporation or organization) File Number) Identification No.) 251 Ballardvale Street Wilm |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporati |
|
| May 11, 2023 |
Exhibit 10.1 Execution Version SECOND AMENDMENT TO THE NINTH AMENDED AND RESTATED CREDIT AGREEMENT SECOND AMENDMENT (this “Agreement”) dated as of March 30, 2023 relating to the Ninth Amended and Restated Credit Agreement dated as of April 21, 2021 (as amended by the First Amendment, dated as of February 28, 2022 and as further heretofore amended or modified, the “Credit Agreement” and as amended |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED April 1, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (I |
|
| May 11, 2023 |
Charles River Laboratories Announces First-Quarter 2023 Results Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2023 Results – First-Quarter Revenue of $1.03 Billion – – First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 – – Updates 2023 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-May 11, 2023-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023 |
|
| May 1, 2023 |
DEFA14A 1 dp193107defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De |
|
| February 22, 2023 |
Subsidiaries of Charles River Laboratories International, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Nederland B.V. Netherlands 5 Charles River Laboratories Holding SAS France 6 Charles River Laboratories France C.R.L.F. SAS France 7 BioFocus DPI (Holdings) L |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES IN |
|
| February 22, 2023 |
Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance – Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48 and Non-GAAP Earnings per Share of $11.12 – – Provides 2023 |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 22, 2023 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe |
|
| February 9, 2023 |
CRL / Charles River Laboratories Intl. Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Charles River Laboratories International Inc. Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to whic |
|
| January 31, 2023 |
EX-24 2 exhibit24.txt Exhibit 24 POWER OF ATTORNEY Effective as of the date hereof, the undersigned does hereby appoint Stephanie J. Brown, with full power of substitution, as the true and lawful attorney of the undersigned, with full power and authority to execute such documents and to make such regulatory or other filings and amendments thereto as shall from time to time be required pursuant to |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 30, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| November 2, 2022 |
Charles River Laboratories Announces Third-Quarter 2022 Results Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2022 Results ? Third-Quarter Revenue of $989.2 Million ? ? Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 ? ? Narrows 2022 Revenue Growth and Earnings Per Share Guidance ? ? Announces Planned Divestiture of Avian Vaccine Business ? WILMINGTON, Mass.-(BUSINESS WIRE)-November 2, 2022-Charles Rive |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 24, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 3, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 25, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| August 3, 2022 |
Charles River Laboratories Announces Second-Quarter 2022 Results Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2022 Results – Second-Quarter Revenue of $973.1 Million – – Second-Quarter GAAP Earnings per Share of $2.13 and Non-GAAP Earnings per Share of $2.77 – – Reduces 2022 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-August 3, 2022-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter |
|
| June 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 8, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporati |
|
| May 26, 2022 |
SD 1 dp173953sd.htm FORM SD OMB APPROVAL OMB Number: 3235-0697 Expires: July 31, 2024 Estimated average burden hours per response...477.89 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or |
|
| May 12, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporati |
|
| May 4, 2022 |
Exhibit 10.1 March 4, 2022 Flavia Pease [***] Subject: Employment Offer Letter Dear Flavia, Charles River Laboratories, Inc. (?Charles River?) is pleased to offer you the position of Executive Vice President, Chief Financial Officer, beginning on a mutually agreed upon date in 2022. In this role, you will report directly to me, and will work remotely from your home in [***]. This full-time positio |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 26, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 4, 2022 |
Charles River Laboratories Announces First-Quarter 2022 Results Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2022 Results ? First-Quarter Revenue of $913.9 Million ? ? First-Quarter GAAP Earnings per Share of $1.81 and Non-GAAP Earnings per Share of $2.75 ? ? Updates 2022 Guidance ? WILMINGTON, Mass.-(BUSINESS WIRE)-May 4, 2022-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2022 |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (IR |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 30, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ????) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 28, 2022 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 28, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| February 16, 2022 |
Subsidiaries of Charles River Laboratories International, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint?Constant S.A. Quebec, Canada 4 Charles River Nederland B.V. Netherlands 5 Charles River Laboratories Holding SAS France 6 Charles River Laboratories France C.R.L.F. SAS France 7 BioFocus DPI (Holdings) L |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 16, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe |
|
| February 16, 2022 |
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results ? Fourth-Quarter Revenue of $905.1 Million and Full-Year Revenue of $3.54 Billion ? ? Fourth-Quarter GAAP Earnings per Share of $2.67 and Non-GAAP Earnings per Share of $2.49 ? ? Full-Year GAAP Earnings per Share of $7.60 and Non-GAAP Earnings per Share of $10.32 ? ? Reaffirms 2022 Guidance ? WILMINGTON, Ma |
|
| February 16, 2022 |
Exhibit 10.18 Private & Confidential Mr D.R. Smith [***] 14 February 2022 Dear David, Compensation changes & Succession terms The following has been decided in respect of your personal compensation: A.Your basic annual salary shall increase to ?479,981 with effect from 1st of April 2022. B.In accordance with, and as per, clause 5.3 of your service agreement dated 1 December 2020 (?Service Agreemen |
|
| February 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 25, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES IN |
|
| February 9, 2022 |
CRL / Charles River Laboratories Intl. Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Charles River Laboratories International Inc. Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to whic |
|
| January 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 11, 2022 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| January 11, 2022 |
aex991xcrljpm2022present EVERY STEP OF THE WAY © 2022 Charles River Laboratories International, Inc. |
|
| December 27, 2021 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2018 INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT (the ?Award Agreement?) This Performance Share Unit Award (the ?Award?) is granted as of December 25, 2021 by Charles River Laboratories International, Inc. (the ?Company?) to Joseph W. LaPlume (the ?Participant?) on the terms and conditions as set forth in this Award Agreement and in the 2018 |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 22, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| December 27, 2021 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Unless defined in this Restricted Stock Unit Award (this ?Award Document?), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the ?Plan?). Pursuant to Section 4(c) of the Plan, you have been granted rest |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| December 15, 2021 |
Sixth Amended and Restated By-Laws of Charles River Laboratories International, Inc. Exhibit 3.1 SIXTH AMENDED AND RESTATED BY-LAWS OF CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SIXTH AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS ARTICLE I - Stockholders 3 1.1 Place of Meetings 3 1.2 Annual Meeting 3 1.3 Special Meetings 3 1.4 Notice of Meeting 3 1.5 Voting List 4 1.6 Quorum 4 1.7 Adjournments 4 1.8 Voting and Proxies 4 1.9 Proxy Representation 4 1.10 Action at Meeting; Major |
|
| November 12, 2021 |
CHARLES RIVER LABORATORIES PROMOTES BIRGIT GIRSHICK TO CHIEF OPERATING OFFICER Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES PROMOTES BIRGIT GIRSHICK TO CHIEF OPERATING OFFICER WILMINGTON, MA, November 11, 2021 ? Charles River Laboratories International, Inc. (NYSE: CRL) today announced that Birgit Girshick has been promoted to the position of Chief Operating Officer, effective immediately. In her most recent role as Corporate Executive Vice President, Ms. Girshick ha |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2021 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction of i |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 9, 2021 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction of in |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 25, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number |
|
| November 3, 2021 |
Charles River Laboratories Announces Third-Quarter 2021 Results Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2021 Results ? Third-Quarter Revenue of $895.9 Million ? ? Third-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.70 ? ? Updates 2021 Guidance ? WILMINGTON, Mass.-(BUSINESS WIRE)-November 3, 2021-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 4, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) |
|
| August 4, 2021 |
Charles River Laboratories Announces Second-Quarter 2021 Results Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2021 Results Second-Quarter Revenue of $914.6 Million Second-Quarter GAAP Earnings per Share of $1.72 and Non-GAAP Earnings per Share of $2.61 Increases 2021 Guidance WILMINGTON, Mass.-(BUSINESS WIRE)-August 4, 2021-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2021. F |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 26, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 28, 2021 |
SD 1 dp151959sd.htm FORM SD OMB APPROVAL OMB Number: 3235-0697 Expires: March 31, 2023 Estimated average burden hours per response.480.61 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) State of Delaware 001-15943 06-1397316 (State or o |
|
| May 18, 2021 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 99.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?) is hereby entered into as of May 18, 2021 by and between Charles River Laboratories International, Inc., a Delaware corporation (the ?Company?), and James C. Foster, an individual (the ?Executive?) (hereinafter collectively referred |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of Inco |
|
| May 10, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio |
|
| May 4, 2021 |
Statement of Eligibility of U.S. Bank National Association on Form T-1 for Senior Debt Indenture. EX-25.1 6 dp150175ex2501.htm EXHIBIT 25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its cha |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 27, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 4, 2021 |
Exhibit 25.2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer Identific |
|
| May 4, 2021 |
Charles River Laboratories amended and restated Deferred Compensation Plan, as amended Exhibit 10.3 AMENDED AND RESTATED DEFERRED COMPENSATION PLAN DOCUMENT February 8, 2006 (Amended December 2, 2008, July 20, 2011 and April 22, 2021) ARTICLE 1.Introduction Charles River Laboratories hereby establishes the Charles River Laboratories Deferred Compensation Plan effective as of January 1, 2006. The Company has established the Plan to attract, retain and motivate certain of its key empl |
|
| May 4, 2021 |
Form of Senior Debt Indenture between the Registrant and U.S. Bank National Association. Exhibit 4.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK NATIONAL ASSOCIATION as Trustee Senior Indenture Dated as of , 20 table of contents Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 4 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 5 ART |
|
| May 4, 2021 |
As filed with the Securities and Exchange Commission on May 4, 2021 Registration No. |
|
| May 4, 2021 |
Form of Subordinated Debt Indenture between the Registrant and U.S. Bank National Association. Exhibit 4.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK NATIONAL ASSOCIATION as Trustee Subordinated Indenture Dated as of , 20 table of contents Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 6 Section 1.04. Rules of Construction |
|
| May 4, 2021 |
Executive Incentive Compensation Program effective January 1, 2021 Exhibit 10.2 PURPOSE The Executive Incentive Compensation Program (?EICP? or the ?Program?) of Charles River Laboratories, Inc. (the ?Company?) is designed to focus employees at the Vice President (?VP?) level and higher on the achievement of organizational, financial and operational goals that have been identified as important for the success of the Company. The Program is also intended to attrac |
|
| May 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 4, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (IR |
|
| May 4, 2021 |
Charles River Laboratories Announces First-Quarter 2021 Results Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2021 Results ? First-Quarter Revenue of $824.6 Million ? ? First-Quarter GAAP Earnings per Share of $1.20 and Non-GAAP Earnings per Share of $2.53 ? ? Updates 2021 Guidance ? WILMINGTON, Mass.-(BUSINESS WIRE)-May 4, 2021-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2021 |
|
| May 4, 2021 |
Exhibit 10.1 Private & Confidential Charles River Discovery Research Services Uk Limited (1) & David Ross Smith (2) SERVICE AGREEMENT THIS AGREEMENT IS A DEED and is made on 2020 BETWEEN: (1)Charles River Discovery Research Services UK Limited (Registered Company Number 04622227) whose registered office is at Robinson Building Chesterford Research Park, Little Chesterford, Saffron Walden CB10 1XL |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 21, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of In |
|
| April 23, 2021 |
EX-10.1 2 dp149793ex1001.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version NINTH AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 21, 2021 among CHARLES RIVER LABORATORIES INTERNATIONAL, INC., The Subsidiary Borrowers Party Hereto, The Lenders Party Hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent BANK OF AMERICA, N.A., CITIBANK, N.A., MUFG BANK, LTD., TD BANK, N.A. and WELLS FARGO |
|
| March 29, 2021 |
CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF COGNATE BIOSERVICES Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF COGNATE BIOSERVICES WILMINGTON, MA, March 29, 2021 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Cognate BioServices, Inc. for approximately $875 million, subject to customary closing adjustments. Cognate BioServices is a pre |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2021 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction of inco |
|
| March 26, 2021 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 23, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of In |
|
| March 23, 2021 |
CHARLES RIVER LABORATORIES ANNOUNCES CLOSING OF SENIOR NOTES OFFERING Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES CLOSING OF SENIOR NOTES OFFERING WILMINGTON, Mass., March 23, 2021?Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 3.750% senior notes due 2029 (the ?2029 notes?) and $500 million in aggregate principal a |
|
| March 23, 2021 |
Exhibit 4.1 Execution Version Charles River Laboratories International, Inc. INDENTURE Dated as of March 23, 2021 U.S. Bank National Association as Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 SECTION 1.1. Definitions 1 SECTION 1.2. Concerning the Trust Indenture Act 6 SECTION 1.3. Rules of Construction 6 ARTICLE II THE SECURITIES 7 SECTION 2.1. Issuable in |
|
| March 23, 2021 |
Exhibit 4.2 Execution Version CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as Issuer EACH OF THE GUARANTORS PARTY HERETO as Guarantors U.S. BANK NATIONAL ASSOCIATION as Trustee First Supplemental Indenture Dated as of March 23, 2021 to the Indenture dated as of March 23, 2021 3.750% Senior Notes due 2029 4.000% Senior Notes due 2031 TABLE OF CONTENTS PAGE ARTICLE 1. DEFINITIONS AND OTHER PROVISI |
|
| March 9, 2021 |
CHARLES RIVER LABORATORIES PRICES $1 BILLION OF SENIOR NOTES Exhibit 99.2 NEWS RELEASE CHARLES RIVER LABORATORIES PRICES $1 BILLION OF SENIOR NOTES WILMINGTON, Mass., March 9, 2021 ? Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it priced its private offering (the ?offering?) of $500 million in aggregate principal amount of 3.750% senior notes due 2029 (the ?2029 notes?) and $500 million in aggregate principal amount of 4.0 |
|
| March 9, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 8, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) 001-15943 (Commission File Number) Delaware 06-1397316 (State of Inc |
|
| March 9, 2021 |
CHARLES RIVER LABORATORIES ANNOUNCES PLANNED OFFERING OF $1 BILLION OF SENIOR NOTES Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES PLANNED OFFERING OF $1 BILLION OF SENIOR NOTES WILMINGTON, Mass., March 8, 2021 ? Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $1 billion aggregate principal amount of senior notes due 2029 and 2031 (the ?notes?) in an unregistered offering, subject to market conditions. Charles Ri |
|
| February 17, 2021 |
Exhibit 2.1 agreement and plan of merger BY AND AMONG CHARLES RIVER LABORATORIES INTERNATIONAL, INC., MEMPHIS MERGER SUB, INC., cognate bioservices, inc. AND THE SELLERS’ REPRESENTATIVE named HEREIN DATED AS OF February 17, 2021 TABLE OF CONTENTS Page Article 1 MERGER 2 1.1 Rollover and Merger 2 1.2 The Closing and the Effective Time 2 1.3 Effect of the Merger 2 1.4 Organizational Documents of the |
|
| February 17, 2021 |
Subsidiaries of Charles River Laboratories International, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint?Constant S.A. Quebec, Canada 4 Charles River Holdings LLC Delaware 5 Ballardvale C.V. Netherlands 6 Charles River Nederland B.V. Netherlands 7 Charles River Laboratories Holding SAS France 8 Charles Rive |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 26, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABO |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 17, 2021 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 17, 2021 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe |
|
| February 17, 2021 |
Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2020 Results and Provides 2021 Guidance ? Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion ? ? Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 ? ? Full-Year GAAP Earnings per Share of $7.20 and Non-GAAP Earnings per Share of $8.13 ? ? Provides 2021 |
|
| February 17, 2021 |
Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES TO ACQUIRE COGNATE BIOSERVICES TO CREATE A PREMIER SCIENTIFIC PARTNER FOR CELL AND GENE THERAPY DEVELOPMENT ? Significantly Expands Charles River?s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector ? ? Combines Cognate?s Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution from Discovery |
|
| February 17, 2021 |
Exhibit 10.1 SUPPORT AGREEMENT This Support Agreement (this ?Agreement?) is dated as of February 17, 2021, by and among Charles River Laboratories International, Inc., a Delaware corporation (?Buyer?), and each of the equityholder(s) of Cognate BioServices, Inc., a Delaware corporation (the ?Company?) listed on the signature pages hereto (each, a ?Holder?). For purposes of this Agreement, Buyer an |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Charles River Laboratories International Inc. Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to whic |
|
| December 31, 2020 |
United States securities and exchange commission logo December 31, 2020 James Foster Chief Executive Officer Charles River Laboratories International, Inc. |
|
| December 31, 2020 |
United States securities and exchange commission logo December 31, 2020 James Foster Chief Executive Officer Charles River Laboratories International, Inc. |
|
| December 17, 2020 |
December 17, 2020 BY EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D. |
|
| December 7, 2020 |
United States securities and exchange commission logo December 7, 2020 James Foster Chief Executive Officer Charles River Laboratories International, Inc. |
|
| December 7, 2020 |
United States securities and exchange commission logo December 7, 2020 James Foster Chief Executive Officer Charles River Laboratories International, Inc. |
|
| November 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R |
|
| November 9, 2020 |
Agreement between David Smith and Charles River Laboratories, Inc. effective October 26, 2020 Exhibit 10.1 PERSONAL AND CONFIDENTIAL October 26, 2020 David Smith c/o Charles River Laboratories, Inc. 251 Ballardvale Street Wilmington, MA 01887 David: The purpose of this letter is to summarize the transfer of your employment from Wilmington, MA, U.S. (your “origin location”) to Cambridge, England, in the Charles River Discovery Research Services UK LTD entity (your “destination location”), e |
|
| October 29, 2020 |
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 29, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number |
|
| October 29, 2020 |
Charles River Laboratories Announces Third-Quarter 2020 Results Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2020 Results – Third-Quarter Revenue of $743.3 Million – – Third-Quarter GAAP Earnings per Share of $2.03 and Non-GAAP Earnings per Share of $2.33 – – Increases 2020 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-October 29, 2020-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 26, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R |
|
| October 29, 2020 |
Agreement between David Smith and Charles River Laboratories, Inc. effective October 26, 2020 Exhibit 10.1 PERSONAL AND CONFIDENTIAL October 26, 2020 David Smith Apartment 31 8 Simpson Loan Edinburgh EH3 9GS David: The purpose of this letter is to summarize the transfer of your employment from Wilmington, MA, U.S. (your “origin location”) to Cambridge, England, in the Charles River Discovery Research Services UK LTD entity (your “destination location”), effective as of December 1, 2020. As |
|
| October 19, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 16, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| August 5, 2020 |
Exhibit 10.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Non-Qualified Stock Option Granted Under 2018 Incentive Plan The Company's most recent Annual Report to Shareholders containing the Company’s audited financial statements for the last three years and its Annual Report on Form 10-K is available on the Company's website at http://www.criver.com. You are urged to review those documents befor |
|
| August 5, 2020 |
Exhibit 10.3 FORM OF CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2018 INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”) This Performance Share Unit Award (the “Award”) is granted as of May 29, 2020 by Charles River Laboratories International, Inc. (the “Company”) to «FN» «LN» (the “Participant”) on the terms and conditions as set forth in this Award Agreement and in |
|
| August 5, 2020 |
Charles River Laboratories Announces Second-Quarter 2020 Results Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2020 Results – Second-Quarter Revenue of $682.6 Million – – Second-Quarter GAAP Earnings per Share of $1.34 and Non-GAAP Earnings per Share of $1.58 – – Increases 2020 Guidance – – Announces Proposed Acquisition of Cellero in the High-Growth Cell Therapy Market – WILMINGTON, Mass.-(BUSINESS WIRE)-August 5, 2020-Charles River Laborato |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 5, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) |
|
| August 5, 2020 |
Exhibit 10.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Unless defined in this Restricted Stock Unit Award (this “Award Document”), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the “Plan”). Pursuant to Section 4(c) of the Plan, you have been |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 27, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 28, 2020 |
OMB APPROVAL OMB Number: 3235-0697 Expires: March 31, 2023 Estimated average burden hours per response. |
|
| May 21, 2020 |
As filed with the Securities and Exchange Commission on May 21, 2020 Registration No. |
|
| May 8, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio |
|
| May 7, 2020 |
Exhibit 10.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. AMENDED AND RESTATED 2018 INCENTIVE PLAN Originally adopted by the Board of Directors On March 20, 2018 Approved at Annual Meeting of Shareholders On May 8, 2018 Amended by the Board of Directors On March 14, 2020 Amendment and Restatement Approved at Annual Meeting of Shareholders On May 6, 2020 1.ADMINISTRATION Subject to the express pr |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) (IR |
|
| May 7, 2020 |
Charles River Laboratories Announces First-Quarter 2020 Results Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2020 Results – First-Quarter Revenue of $707.1 Million – – First-Quarter GAAP Earnings per Share of $1.02 and Non-GAAP Earnings per Share of $1.84 – – Revises 2020 Guidance Due to COVID-19 Impact – WILMINGTON, Mass.-(BUSINESS WIRE)-May 7, 2020-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for th |
|
| May 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 28, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| March 26, 2020 |
CRL / Charles River Laboratories International, Inc. DEF 14A - - DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| February 12, 2020 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Charles River Laboratories International Inc Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which |
|
| February 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABO |
|
| February 11, 2020 |
Exhibit 4.2 DESCRIPTION OF SECURITIES The following description is based upon our second amended and restated certificate of incorporation, our fifth amended and restated by-laws and applicable provisions of law. We have summarized certain portions of the second amended and restated certificate of incorporation and third amended and restated by-laws below. The summary is not complete. The second a |
|
| February 11, 2020 |
Subsidiaries of Charles River Laboratories International, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Holdings LLC Delaware 5 Ballardvale C.V. Netherlands 6 Charles River Nederland B.V. Netherlands 7 Charles River Laboratories Holding SAS France 8 Charles Rive |
|
| February 11, 2020 |
Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance – Fourth-Quarter Revenue of $691.1 Million and Full-Year Revenue of $2.62 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.61 and Non-GAAP Earnings per Share of $2.01 – – Full-Year GAAP Earnings per Share of $5.07 and Non-GAAP Earnings per Share of $6.73 – – Provides 2020 |
|
| February 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 11, 2020 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Numbe |
|
| November 6, 2019 |
Charles River Laboratories Announces Third-Quarter 2019 Results Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2019 Results – Third-Quarter Revenue of $668.0 Million – – Third-Quarter GAAP Earnings per Share of $1.46 and Non-GAAP Earnings per Share of $1.69 – – Updates 2019 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-November 6, 2019-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of |
|
| November 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number |
|
| November 6, 2019 |
Exhibit 10.2 SECOND AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CREDIT AGREEMENT SECOND AMENDMENT (this “Amendment”) dated as of September 25, 2019 relating to the Eighth Amended and Restated Credit Agreement dated as of March 26, 2018 (as heretofore amended or modified, the “Credit Agreement”) among Charles River Laboratories International, Inc. (the “Parent Borrower”), the Subsidiary Borrowers |
|
| November 6, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 28, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R |
|
| November 6, 2019 |
Agreement between David Johst and Charles River Laboratories, Inc. effective July 26, 2019 Exhibit 10.1 AGREEMENT This Agreement (the “Agreement”), with an effective date of July 26, 2019, is entered into by Charles River Laboratories, Inc., with its principal place of business at 251 Ballardvale Street, Wilmington, Massachusetts 01887 (the “Company”) and Mr. David P. Johst, an individual residing at 7 Meadow View Lane, Andover, MA 01810 (the “Employee”). The Employee and the Company re |
|
| November 6, 2019 |
Exhibit 10.3 THIRD AMENDMENT TO THE EIGHTH AMENDED AND RESTATED CREDIT AGREEMENT THIRD AMENDMENT (this “Amendment”) dated as of November 4, 2019 relating to the Eighth Amended and Restated Credit Agreement dated as of March 26, 2018 (as heretofore amended or modified, the “Credit Agreement”) among Charles River Laboratories International, Inc. (the “Parent Borrower”), the Subsidiary Borrowers part |
|
| October 23, 2019 |
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as Issuer EACH OF THE GUARANTORS PARTY HERETO as Guarantors MUFG UNION BANK, N.A. as Trustee Second Supplemental Indenture Dated as of October 23, 2019 to the Indenture dated as of April 3, 2018 4.250% Senior Notes due 2028 TABLE OF CONTENTS PAGE ARTICLE 1. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 2 Section 1.01 Scope of Supplemental In |
|
| October 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 23, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| October 23, 2019 |
CHARLES RIVER LABORATORIES ANNOUNCES CLOSING OF SENIOR NOTES OFFERING Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES CLOSING OF SENIOR NOTES OFFERING WILMINGTON, MA, October 23, 2019 - Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 4.25% senior notes due 2028 (the “notes”) in an unregistered offering. The notes have no |
|
| October 21, 2019 |
Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 21, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| October 21, 2019 |
Excerpts from the Preliminary Offering Memorandum dated October 21, 2019 Exhibit 99.1 Excerpts from the Preliminary Offering Memorandum dated October 21, 2019 Recent developments - Preliminary and unaudited estimates of the Company’s selected third quarter 2019 results Set forth below are preliminary estimates of unaudited selected financial information for the three months ended September 28, 2019 and actual unaudited financial results for the three months ended Septe |
|
| October 21, 2019 |
CHARLES RIVER LABORATORIES ANNOUNCES OFFERING OF $500 MILLION OF SENIOR NOTES Exhibit 99.2 NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES OFFERING OF $500 MILLION OF SENIOR NOTES WILMINGTON, MA, October 21, 2019 - Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it intends to offer $500 million in aggregate principal amount of senior notes due 2028 (the “notes”) in an unregistered offering, subject to market conditions. Charles River intend |
|
| October 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 1, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpor |
|
| August 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 30, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporat |
|
| July 31, 2019 |
Charles River Laboratories Announces Second-Quarter 2019 Results Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2019 Results – Second-Quarter Revenue of $657.6 Million – – Second-Quarter GAAP Earnings per Share of $0.88 and Non-GAAP Earnings per Share of $1.63 – – Updates 2019 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-July 31, 2019-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter o |
|
| July 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 31, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other (Commission File Number) ( |
|
| July 31, 2019 |
Exhibit 4.1 FORM OF CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2018 INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD AGREEMENT (the “Award Agreement”) This Performance Share Unit Award (the “Award”) is granted as of February xx, 20xx by Charles River Laboratories International, Inc. (the “Company”) to «FN» «LN» (the “Participant”) on the terms and conditions as set forth in this Award Agreement and |
|
| July 31, 2019 |
Exhibit 10.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. GRANTED UNDER 2018 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD Unless defined in this Restricted Stock Unit Award (this “Award Document”), capitalized terms will have the same meanings ascribed to them in the Charles River Laboratories International, Inc. 2018 Incentive Plan (the “Plan”). Pursuant to Section 4(c) and Section 4(d) of the Pl |
|
| July 31, 2019 |
Exhibit 10.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Non-Qualified Stock Option Granted Under 2018 Incentive Plan The Company's most recent Annual Report to Shareholders containing the Company’s audited financial statements for the last three years and its Annual Report on Form 10-K is available on the Company's website at http://www.criver.com. You are urged to review those documents befor |
|
| July 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 29, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 30, 2019 |
CRL / Charles River Laboratories International, Inc. SD - - FORM SD OMB APPROVAL OMB Number: 3235-0697 Expires: June 30, 2019 Estimated average burden hours per response…. |
|
| May 22, 2019 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2019 Charles River Laboratories International, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| May 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 30, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorporatio |
|
| May 7, 2019 |
Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2019 Results – First-Quarter Revenue of $604.6 Million – – First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share of $1.40 – – Reaffirms 2019 Guidance Including Citoxlab – WILMINGTON, Mass.-(BUSINESS WIRE)-May 7, 2019-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the |
|
| May 1, 2019 |
Share Sale and Purchase Agreement dated April 27, 2019 Exhibit 2.1 SHARE SALE AND PURCHASE AGREEMENT between (1)AXA LBO FUND V SUPPLEMENTARY FPCI (2)JEAN FRANCOIS LE BIGOT (3)THE OTHER CTL SELLERS, as defined below (4)THE CANADIAN CTL SELLERS, as defined below (5)BLUE JAZZ SAS (6)BLUE TANGO SAS (together the “Sellers”) (7)CHARLES RIVER NEDERLAND B.V. (the “Purchaser”) (8)CHARLES RIVER LABORATORIES INTERNATIONAL, INC (the “Parent”) (9)CTL INTERNATIONAL |
|
| May 1, 2019 |
CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF CITOXLAB Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF CITOXLAB WILMINGTON, MA, April 29, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of Citoxlab for €448 million in cash (or approximately $500 million based on current exchange rates), subject to customary closing adjustments |
|
| May 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2019 Charles River Laboratories International, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Inco |
|
| April 30, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 30, 2019 Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction of inc |
|
| April 4, 2019 |
CRL / Charles River Laboratories International, Inc. DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 15, 2019 |
EX-2.2 Exhibit 2.2 Execution version AXA LBO FUND V SUPPLEMENTARY FPCI JEAN FRANCOIS LE BIGOT ROY FORSTER PATRICK SPIES BLUE JAZZ SAS BLUE TANGO SAS CTL INTERNATIONAL SAS CHARLES RIVER NEDERLAND B.V. EXCLUSIVITY AGREEMENT FEBRUARY 12, 2019 CONTENTS Articles Page 1. Definitions 5 2. Exclusivity 5 3. Consultation of the employee representative bodies 7 4. SPA Provisions 8 5. Break-up fees |
|
| February 15, 2019 |
EX-99.1 Exhibit 99.1 NEWS RELEASE CHARLES RIVER LABORATORIES SIGNS BINDING OFFER TO ACQUIRE CITOXLAB – Further Strengthens Charles River’s Position as the Leading Global Early-Stage CRO – – Transaction Expected to be Accretive to Non-GAAP EPS by Approximately $0.15 in 2019 and At Least $0.35 in 2020 – WILMINGTON, MA, February 13, 2019 – Charles River Laboratories International, Inc. (NYSE: CRL) an |
|
| February 15, 2019 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2019 Charles River Laboratories International, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction |
|
| February 15, 2019 |
EX-2.1 Exhibit 2.1 Execution version February 12, 2019 From: CHARLES RIVER NEDERLAND B.V., a Dutch Besloten Vennootschap, having its registered office located at Darwinweg 24, 2333CR Leiden (Netherlands) identified under number 000010497803, duly represented for the purpose hereof hereinafter, the Offeror With the participation of: CHARLES RIVER LABORATORIES INTERNATIONAL, INC., a Delaware corpora |
|
| February 13, 2019 |
Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2018 Results and Provides 2019 Guidance – Fourth-Quarter Revenue of $601.5 Million and Full-Year Revenue of $2.27 Billion – – Fourth-Quarter GAAP Earnings per Share of $1.21 and Non-GAAP Earnings per Share of $1.49 – – Full-Year GAAP Earnings per Share of $4.59 and Non-GAAP Earnings per Share of $6.03 – – Provides 2019 |
|
| February 13, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 13, 2019 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorp |
|
| February 13, 2019 |
CRL / Charles River Laboratories International, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 29, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABO |
|
| February 13, 2019 |
Subsidiaries of Charles River Laboratories International, Inc. Exhibit 21.1 SUBSIDIARIES Subsidiary Jurisdiction of Organization 1 Charles River Laboratories, Inc. Delaware 2 Charles River UK Limited United Kingdom (England) 3 Charles River Laboratories Saint‑Constant S.A. Quebec, Canada 4 Charles River Holdings LLC Delaware 5 Ballardvale C.V. Netherlands 6 Charles River Nederland B.V. Netherlands 7 Charles River Laboratories Holding SAS France 8 Charles Rive |
|
| February 11, 2019 |
CRL / Charles River Laboratories International, Inc. / VANGUARD GROUP INC Passive Investment charlesriverlaboratoriesinte.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8 )* Name of issuer: Charles River Laboratories International Inc Title of Class of Securities: Common Stock CUSIP Number: 159864107 Date of Event Which Requires Filing of this Statement: Decemb |
|
| November 7, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2018 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpo |
|
| November 7, 2018 |
Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2018 Results – Third-Quarter Revenue of $585.3 Million – – Third-Quarter GAAP Earnings per Share of $1.22 and Non-GAAP Earnings per Share of $1.53 – – Updates 2018 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-November 7, 2018-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of |
|
| November 7, 2018 |
CRL / Charles River Laboratories International, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 29, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES R |
|
| November 7, 2018 |
Consulting Agreement between Davide Molho and Charles River Laboratories, Inc. dated August 28, 2018 Exhibit 10.3 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the "Consulting Agreement"), made this 28th day of August, 2018 (the “Effective Date”), is entered into by Charles River Laboratories, Inc., with its principal place of business at 251 Ballardvale Street, Wilmington, Massachusetts 01887 (the "Company"), and Dr. Davide Molho (the "Consultant"). The Company desires to retain the services o |
|
| November 7, 2018 |
Exhibit 10.1 CONFIDENTIAL To: Davide Molho From: Jim Foster Date: August 1, 2018 (Revised on August 28, 2018) Subject: Separation Agreement The purpose of this memorandum (“Memorandum”) is to formally advise you of a decision by Charles River Laboratories (the “Company”) to terminate your employment without cause and due to a position elimination pursuant to the terms of the 2010 Charles River Cor |
|
| November 7, 2018 |
Exhibit 10.2 Revised Date: August 28, 2018 Original Date: August 1, 2018 Personal and Confidential Dr. Davide A. Molho 56 W. Cedar Street Boston, MA 02114 Dear Davide: By this letter (“Letter Agreement”), we are offering to agree to the following arrangement with you concerning your separation from employment with Charles River Laboratories, Inc. (the “Company”). You have until August 28, 2018 to |
|
| October 3, 2018 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2018 Charles River Laboratories International, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of |
|
| August 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 28, 2018 Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) Delaware 001-15943 06-1397316 (State or other jurisdiction (Commi |
|
| August 8, 2018 |
Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2018 Results from Continuing Operations – Second-Quarter Revenue of $585.3 Million – – Second-Quarter GAAP Earnings per Share of $1.06 and Non-GAAP Earnings per Share of $1.62 – – Increases 2018 Revenue Growth and Earnings per Share Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-August 8, 2018-Charles River Laboratories International, |
|
| August 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2018 Date of Report (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-15943 06-1397316 (State or Other Jurisdiction of Incorpora |
|
| August 8, 2018 |
Charles River Laboratories International, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 2, 2018 Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) Delawar |
|
| August 8, 2018 |
CRL / Charles River Laboratories International, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| June 14, 2018 |
Financial Statements and Exhibits 8-K/A 1 dp920888ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 3, 2018 Commission File Number Exact Name of Registrant as Specified in Charter; State of Incorporation; Address and Telephon |
|
| June 14, 2018 |
ITEM 9.01 (b) UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 ITEM 9.01 (b) UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 3, 2018, Charles River Laboratories International, Inc. (“Charles River” or the “Company”), Forest Acquisition Corporation, a wholly-owned subsidiary of Charles River (“Merger Sub”), ACP Mountain Holdings, Inc. (“ACP”) and Avista Capital Partners IV GP, LP, in its capacity as Stockholder’s Representati |
|
| June 14, 2018 |
See Notes to Consolidated Financial Statements Exhibit 99.1 ITEM 9.01 (a) FINANCIAL STATEMENTS OF BUSINESSES ACQUIRED ACP Mountain holdings, Inc. INDEPENDENT AUDITORS’ REPORT CONSOLIDATED FINANCIAL STATEMENTS: Consolidated Balance Sheet as of December 31, 2017 Consolidated Statement of Operations and Comprehensive Income for the Year ended December 31, 2017 Consolidated Statement of Changes in Shareholders’ Equity for the Year ended December 3 |
|
| June 14, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 14, 2018 Commission File Number Exact Name of Registrant as Specified in Charter; State of Incorporation; Address and Telephone Number Former Name or Former Address, if Changed s |
|
| May 31, 2018 |
CRL / Charles River Laboratories International, Inc. FORM SD OMB APPROVAL OMB Number: 3235-0697 Expires: June 30, 2019 Estimated average burden hours per response…. |
|
| May 18, 2018 |
CRL / Charles River Laboratories International, Inc. FORM S-8 As filed with the Securities and Exchange Commission on May 18, 2018 Registration No. |
|
| May 14, 2018 |
Submission of Matters to a Vote of Security Holders Charles River Laboratories International, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2018 Charles River Laboratories International, Inc. (Exact name of registrant as specified in its charter) Delaware 0 |
|
| May 10, 2018 |
CRL / Charles River Laboratories International, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER |
|
| May 10, 2018 |
Charles River Laboratories International, Inc. 2018 Incentive Plan dated March 20, 2018 Exhibit 10.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 2018 INCENTIVE PLAN Originally adopted by the Board of Directors On March 20, 2018 1.ADMINISTRATION Subject to the express provisions of the Plan, the Administrator has the authority to interpret the Plan; determine eligibility for and grant Awards; determine, modify or waive the terms and conditions of any Award; prescribe forms, rules a |
|
| May 10, 2018 |
Exhibit 99.1 Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations – First-Quarter Revenue of $494.0 Million – – First-Quarter GAAP Earnings per Share of $1.08 and Non-GAAP Earnings per Share of $1.38 – – Updates 2018 Guidance – WILMINGTON, Mass.-(BUSINESS WIRE)-May 10, 2018-Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results f |
|
| May 10, 2018 |
8-K 1 a51804082.htm CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2018 Date of Report: (Date of earliest event reported) CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Charter) D |
|
| May 8, 2018 |
Form of Subordinated Debt Indenture between the Registrant and U.S. Bank National Association. Exhibit 4.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. as the Company and U.S. BANK NATIONAL ASSOCIATION as Trustee Subordinated Indenture Dated as of , 20 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01. Definitions. 1 Section 1.02. Other Definitions 8 Section 1.03. Incorporation by Reference of Trust Indenture Act 8 Section 1.04. Rules of Construction |
